Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Pfizer is likely to show GSK significant competition
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
Subscribe To Our Newsletter & Stay Updated
